Recent advances in the field of Salmonella Typhi vaccines

Human Vaccines

Volumn 6, Issue 5, 2010, Pages 379-384

  Paterson, Gavin K ^a   Maskell, Duncan J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Bacterial infection; Live attenuated vaccine; Polysaccharide vaccine; Salmonella Typhi; Salmonella Typhimurium; Subunit vaccine; Typhoid fever; Vaccine

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; COTRIMOXAZOLE; LIVE VACCINE; TYPHOID VACCINE;

CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MEDICAL RESEARCH; NONHUMAN; PARATYPHOID FEVER; PATHOGENESIS; REVIEW; SALMONELLA ENTERICA; SALMONELLA TYPHI; TYPHOID FEVER; UNSPECIFIED SIDE EFFECT;

EID: 77953717961     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.5.10755     Document Type: Review

References (62)

1. Tindall BJ, Grimont PA, Garrity GM, Euzeby JP. Nomenclature and taxonomy of the genus Salmonella. Int J Syst Evol Microbiol 2005; 55:521-4.
2. Brenner FW, Villar RG, Angulo FJ, Tauxe R, Swaminathan B. Salmonella nomenclature. J Clin Microbiol 2000; 38:2465-7.
3. Board P. Publications Board meeting minutes. Salmonella nomenclature. ASM News 1999; 65:769.
4. Gordon MA, Banda HT, Gondwe M, Gordon SB, Boeree MJ, Walsh AL, et al. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: High mortality and frequent recrudescence. Aids 2002; 16:1633-41. (Pubitemid 34921109)
5. Gordon MA, Walsh AL, Chaponda M, Soko D, Mbvwinji M, Molyneux ME, Gordon SB. Bacteraemia and mortality among adult medical admissions in Malawi - Predominance of non-typhi Salmonellae and Streptococcus pneumoniae. Journal of Infection 2001; 42:44-9. (Pubitemid 32631799)
6. Graham SM, Walsh AL, Molyneux EM, Phiri AJ, Molyneux ME. Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children. Transactions of the Royal Society of Tropical Medicine and Hygiene 2000; 94:310-4.
7. Morpeth SC, Ramadhani HO, Crump JA. Invasive Non-Typhi Salmonella Disease in Africa. Clinical Infectious Diseases 2009; 49:606-11.
8. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346-53.
9. Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 2008; 21:531-8.
10. Cooke FJ, Wain J. Antibiotic resistance in Salmonella infections. In: Maskell D, Mastroeni P, eds. Salmonella Infection Clinical, Immunological and Molecular Aspects. Cambridge: Cambridge University Press 2006; 25-56.
11. Gröschel DH, Hornick RB. Who Introduced Typhoid Vaccination: Almroth Wright or Richard Pfeiffer? Reviews of Infectious Diseases 1981; 3:1251-4.
12. Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. British Medical Journal 1998; 316:110-6. (Pubitemid 28121109)
13. Germanier R, Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975; 131:553-8.
14. Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007; 25:7848-57.
15. Griot-Wenk ME, Hartmann K, Herzog C, Ackermann J, Maspes B. Excellent long-term safety data established in a recent post-marketing surveillance for the oral tyhpoid fever vaccine, VIVOTIF. Italian Journal of Tropical Medicine 2001; 6:104-5.
16. Wilson RP, Raffatellu M, Chessa D, Winter SE, Tukel C, Baumler AJ. The Vi-capsule prevents Toll-like receptor 4 recognition of Salmonella. Cell Microbiol 2008; 10:876-90.
17. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14:435-8.
18. Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001; 79:625-31.
19. Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 1999; 18:609-20.
20. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981; 291:238-9.
21. Hone DM, Tacket CO, Harris AM, Kay B, Losonsky G, Levine MM. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest 1992; 90:412-20.
22. Tacket CO, Hone DM, Curtiss R, 3rd, Kelly SM, Losonsky G, Guers L, et al. Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun 1992; 60:536-41.
23. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 1992; 10:443-6.
24. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun 1997; 65:452-6.
25. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/ phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996; 173:1408-14.
26. Curtiss R, 3rd, Kelly SM. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun 1987; 55:3035-43.
27. Tacket CO, Kelly SM, Schodel F, Losonsky G, Nataro JP, Edelman R, et al. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun 1997; 65:3381-5.
28. Strugnell RA, Wijburg OLC. Newer vaccines against typhoid fever and gastrointestestinal salmonelloses. In: Mastronei P, Maskell D, eds. Salmonella Infections Clinical, Immunological and Molecular Aspects. Cambridge: Cambridge University Press 2006; 323-36.
29. Hansen-Wester I, Hensel M. Salmonella pathogenicity islands encoding type III secretion systems. Microbes Infect 2001; 3:549-59.
30. Hensel M. Salmonella pathogenicity island 2. Mol Microbiol 2000; 36:1015-23.
31. Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA, et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun 2002; 70:3457-67.
32. Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006; 24:116-23.
33. Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis 2005; 192:360-6.
34. th Conference of the International Society of Travel Medicine (CISTM11). Budapest, Hungary: International Society of Travel Medicine 2009.
35. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909. Infect Immun 2000; 68:4647-52.
36. Tacket CO, Losonsky G, Taylor DN, Baron LS, Kopecko D, Cryz S, Levine MM. Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. J Infect Dis 1991; 163:901-4.
37. Szu SC, Stone AL, Robbins JD, Schneerson R, Robbins JB. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization and immunogenicity in laboratory animals. J Exp Med 1987; 166:1510-24. (Pubitemid 18051440)
38. Szu SC, Taylor DN, Trofa AC, Clements JD, Shiloach J, Sadoff JC, et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 1994; 62:4440-4.
39. Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999; 67:5806-10. (Pubitemid 29508102)
40. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-9.
41. Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003; 349:1390-1.
42. Hamid N, Jain SK. Characterization of an outer membrane protein of Salmonella enterica serovar typhimurium that confers protection against typhoid. Clin Vaccine Immunol 2008; 15:1461-71.
43. Isibasi A, Ortiznavarrete V, Paniagua J, Pelayo R, Gonzalez CR, Garcia JA, Kumate J. Active Protection of Mice against Salmonella typhi by Immunization with Strain-Specific Porins. Vaccine 1992; 10:811-3.
44. Salazar-Gonzalez RM, Maldonado-Bernal C, Ramirez-Cruz NE, Rios-Sarabia N, Beltran-Nava J, Castanon-Gonzalez J, et al. Induction of cellular immune response and anti-Salmonella enterica serovar typhi bactericidal antibodies in healthy volunteers by immunization with a vaccine candidate against typhoid fever. Immunology Letters 2004; 93:115-22.
45. Synnott A, Ohshima K, Nakai Y, Tanji Y. IgA response of BALB/c mice to orally administered Salmonella typhimurium flagellin-displaying T2 bacteriophages. Biotechnol Prog 2009; 25:552-8.
46. Takata T, Shirakawa T, Kawasaki Y, Kinoshita S, Gotoh A, Kano Y, Kawabata M. Genetically engineered Bifidobacterium animalis expressing the Salmonella Isibasi and 1992 and Salmonella Helicobacter pylori defined by human serum antibodies. Vaccine 2009; 27:3251-9.
47. Giefing C, Meinke AL, Hanner M, Henics T, Minh DB, Gelbmann D, et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. Journal of Experimental Medicine 2008; 205:117-31. (Pubitemid 351185720)
48. Meinke A, Henics T, Hanner M, Minh DB, Nagy E. Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. Vaccine 2005; 23:2035-41. (Pubitemid 40341423)
49. Chaudhuri RR, Peters SE, Pleasance SJ, Northen H, Willers C, Paterson GK, et al. Comprehensive identification of Salmonella enterica serovar Typhimurium genes required for infection of BALB/c mice. PLoS Pathog 2009; 5:1000529.
50. Santiviago CA, Reynolds MM, Porwollik S, Choi SH, Long F, Andrews-Polymenis HL, McClelland M. Analysis of pools of targeted Salmonella deletion mutants identifies novel genes affecting fitness during competitive infection in mice. PLoS Pathog 2009; 5:1000477.
51. Paterson GK, Northen H, Cone DB, Willers C, Peters SE, Maskell DJ. Deletion of tolA in Salmonella typhimurium generates an attenuated strain with vaccine potential. Microbiology 2009; 155:220-8.
52. Northen H, Paterson GK, Constantino-Casas F, Bryant CE, Clare S, Mastroeni P, et al. Salmonella enterica serovar Typhimurium mutants completely lacking the F(0) F(1) ATPase are novel live attenuated vaccine strains. Vaccine 2010; 28: 940-49.
53. Peters SE, Paterson GK, Bandularatne ESD, Northen HC, Pleasance SJ, Willers C, et al. Salmonella enterica serovar Typhimurium trxA mutants are protective against virulent challenge, but induce less inflammation than the live-attenuated vaccine strain, SL3261. Infection and Immunity 2010 Jan; 78(1): 326-36.
54. Curtiss R, 3rd, Wanda SY, Gunn BM, Zhang X, Tinge SA, Ananthnarayan V, et al. Salmonella enterica serovar Typhimurium strains with regulated delayed attenuation in vivo. Infect Immun 2009; 77:1071-82.
55. Curtiss R, 3rd, Zhang X, Wanda SY, Konjufca V, Li Y, Gunn B, et al. Induction of host immune responses using Salmonella-vectored vaccines. In: Brogden KA, Minion FC, Cornick N, Staton TB, Zhang Q, Nolan LK, Wannemuehler MJ, eds. Virulence mechanisms of bacterial pathogens. Washington, DC: ASM Press 2007; 297-313.
56. Kong W, Wanda SY, Zhang X, Bollen W, Tinge SA, Roland KL, Curtiss R, 3rd. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment. Proc Natl Acad Sci USA 2008; 105:9361-6.
57. Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, et al. Killed but metabolically active microbes: A new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nature Medicine 2005; 11:853-60. (Pubitemid 41161117)
58. Skoble J, Beaber JW, Yi G, Lovchik JA, Sower LE, Liu W, et al. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Infection and Immunity 2009; 77:1649-63.
59. Lankowski AJ, Hohman EL. Killed but metabolically active Salmonella typhimurium: Application of a new technology to an old vector. Journal of Infectious Diseases 2007; 195:1203-11.
60. Arya SC, Sharma KB. Urgent need for effective vaccine against Salmonella paratyphi A, B and C. Vaccine 1995; 13:1727-8.
61. Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in entericcoated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 1990; 8:81-4.
62. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1:1049-52. (Pubitemid 17061327)